ArticleJournal of clinical microbiology2015
Discordance between Xpert MTB/RIF assay and Bactec MGIT 960 Culture System for detection of rifampin-resistant Mycobacterium tuberculosis isolates in a country with a low tuberculosis (TB) incidence.
Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Xpert MTB/RIF assay for the diagnosis of rifampicin resistance in different regions: a meta-analysis.BMC microbiology · 2019Pooled it
- Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.The Cochrane database of systematic reviews · 2019Pooled it
- Accuracy of nanopore-based targeted next-generation sequencing assay for detection ofJournal of clinical microbiology · 2026Article
- Series 2: Development of a Multiplex Amplicon Next Generation Sequencing Assay for Rapid Assessment of Resistance-Associated Mutations inTropical medicine and infectious disease · 2025Article
- Discordant results between Xpert MTB/RIF assay and Bactec MGIT 960 culture system regarding the detection of rifampin-resistantMicrobiology spectrum · 2024Article
- Evaluation of the GeneXpert MTB/RIF to diagnose tuberculosis in a public health laboratory.Revista de saude publica · 2024Article
- Article
- Discordant results of Xpert MTB/Rif assay and BACTEC MGIT 960 liquid culture to detect Mycobacterium tuberculosis in community screening in Vietnam.BMC infectious diseases · 2022Article
- Assessing the utility of the Xpert Mycobacterium tuberculosis/rifampin assay for analysis of bronchoalveolar lavage fluid in patients with suspected pulmonary tuberculosis.Journal of clinical laboratory analysis · 2022Article
- Article
- Integrative utility of long read sequencing-based whole genome analysis and phenotypic assay on differentiating isoniazid-resistant signature of Mycobacterium tuberculosis.Journal of biomedical science · 2021Article
- Review
- Molecular characterization of rpoB gene mutations in isolates from tuberculosis patients in Cubal, Republic of Angola.BMC infectious diseases · 2021Article
- Increasing prevalence of resistance to second-line drugs among multidrug-resistant Mycobacterium tuberculosis isolates in Kuwait.Scientific reports · 2021Article
- Observational
- GeneXpert on patients with human immunodeficiency virus and smear-negative pulmonary tuberculosis.PloS one · 2021Article
- Performance Comparison of GeneXpert MTB/RIF and ProbeTec ET Tests for Rapid Molecular Diagnosis of Extrapulmonary Tuberculosis in a Low TB/MDR-TB Incidence Country.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Article
- Reply to Murray et al., "Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays".Journal of clinical microbiology · 2019Article
- Clinical implications of discrepant results between genotypic MTBDRJournal of thoracic disease · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among 452 samples that were positive by the Xpert MTB/RIF (Xpert) assay and MGIT 960 system (MGIT), 440 and 10 Mycobacterium tuberculosis samples were detected as rifampin susceptible and rifampin resistant, respectively. Two isolates that were rifampin susceptible by the MGIT system were rifampin resistant by the Xpert assay. rpoB sequencing identified a silent (CTG521TTG) mutation in one isolate and a missense (GAC516TAC) mutation in another. The detection of rifampin resistance is imperfect with both the Xpert assay and MGIT system. Any discordant rifampin resistance results should be confirmed by sequencing of the rpoB gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.